Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study

Overview

Journal J Clin Exp Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2022 Jan 24

PMID 35068786

Authors

N A Rajesh

L Drishya

Murali Mohan Raju Ambati

Athi L Narayanan

Maria Alex

Kiran Kumar R

Justin J Abraham

T M Vijayakumar

Affiliations

Soon will be listed here.

Abstract

Background: Saroglitazar-a unique dual peroxisome proliferator-activated receptor agonist was approved marketing authorization in India in 2013 for diabetic dyslipidemia. Postmarketing studies have additionally shown improvement in liver parameters in diabetic dyslipidemia patients with nonalcoholic fatty liver disease (NAFLD) who received saroglitazar.

Aim: The aim of this study was to evaluate the effect of saroglitazar on liver function test, liver fibrosis score by FibroScan, lipid profiles, HbA1c in NAFLD patients with diabetic dyslipidemia in southern India.

Methodology: A prospective, interventional, pilot study was performed to study the safety and efficacy of saroglitazar in NAFLD patients having type 2 diabetes mellitus. About 97 patients were screened, of which 85 patients were involved in the study based on the inclusion criteria. The clinical parameters and liver stiffness were measured at the baseline and also after 12 weeks of treatment with administration of saroglitazar 4 mg once daily. The change in the parameters at the baseline and after the end of the treatment was measured and was subjected to statistical analysis using SPSS software.

Results: The recruited patients received saroglitazar and were followed up for a period of 12 weeks. The clinical parameters such as fasting blood sugar, postprandial blood sugar, HbA1c, total cholesterol, triglycerides, SGPT, and liver stiffness showed significant difference after 12 weeks of treatment when compared with the baseline values. No adverse drug reaction was reported in patients receiving saroglitazar during the study.

Conclusion: Saroglitazar was found to show significant improvement in liver parameters in NAFLD patients with a significant reduction in liver fibrosis and triglycerides level.

Citing Articles

The SVIN-Trial-Just Another Brick in the Wall?.

Mehtani R J Clin Exp Hepatol. 2024; 15(2):102449.

PMID: 39649151 PMC: 11617671. DOI: 10.1016/j.jceh.2024.102449.

Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies.

Pramanik S, Pal P, Ray S World J Methodol. 2024; 14(2):91319.

PMID: 38983664 PMC: 11229880. DOI: 10.5662/wjm.v14.i2.91319.

Emerging Combination of Saroglitazar and Vitamin E for the Treatment of NAFLD and NASH.

Tavaglione F, Loomba R J Clin Exp Hepatol. 2024; 14(5):101449.

PMID: 38881684 PMC: 11170343. DOI: 10.1016/j.jceh.2024.101449.

A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL.

Mir B, Sharma B, Sharma R, Bodh V, Chauhan A, Majeed T J Clin Exp Hepatol. 2024; 14(5):101398.

PMID: 38628977 PMC: 11017282. DOI: 10.1016/j.jceh.2024.101398.

Saroglitazar in Non-alcoholic Fatty Liver Disease From Bench to Bedside: A Comprehensive Review and Sub-group Meta-Analysis.

Roy A, Tewari B, Giri S, Goenka M Cureus. 2023; 15(10):e47493.

PMID: 38022283 PMC: 10663873. DOI: 10.7759/cureus.47493.

References

Qiang S, Nakatsu Y, Seno Y, Fujishiro M, Sakoda H, Kushiyama A . Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr. 2015; 7:104. PMC: 4653899. DOI: 10.1186/s13098-015-0102-8. View

Misra A, Vikram N . Insulin resistance syndrome (metabolic syndrome) and obesity in Asian Indians: evidence and implications. Nutrition. 2004; 20(5):482-91. DOI: 10.1016/j.nut.2004.01.020. View

Xia M, Bian H, Gao X . NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. Front Pharmacol. 2019; 10:877. PMC: 6691129. DOI: 10.3389/fphar.2019.00877. View

Prashanth M, Ganesh H, Vima M, John M, Bandgar T, Joshi S . Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India. 2009; 57:205-10. View

Dharmalingam M, Yamasandhi P . Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Indian J Endocrinol Metab. 2018; 22(3):421-428. PMC: 6063173. DOI: 10.4103/ijem.IJEM_585_17. View

Jani R, Pai V, Jha P, Jariwala G, Mukhopadhyay S, Bhansali A . A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy.... Diabetes Technol Ther. 2013; 16(2):63-71. PMC: 3894674. DOI: 10.1089/dia.2013.0253. View

Wasir J, Misra A . The Metabolic Syndrome in Asian Indians: Impact of Nutritional and Socio-economic Transition in India. Metab Syndr Relat Disord. 2008; 2(1):14-23. DOI: 10.1089/met.2004.2.14. View

Benedict M, Zhang X . Non-alcoholic fatty liver disease: An expanded review. World J Hepatol. 2017; 9(16):715-732. PMC: 5468341. DOI: 10.4254/wjh.v9.i16.715. View

Leite N, Salles G, Araujo A, Villela-Nogueira C, Cardoso C . Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2008; 29(1):113-9. DOI: 10.1111/j.1478-3231.2008.01718.x. View

10.

Misra A, Misra R . Asian indians and insulin resistance syndrome: global perspective. Metab Syndr Relat Disord. 2008; 1(4):277-83. DOI: 10.1089/1540419031361390. View

11.

Xing B, Zhao Y, Dong B, Zhou Y, Lv W, Zhao W . Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. J Diabetes Investig. 2020; 11(5):1238-1247. PMC: 7477503. DOI: 10.1111/jdi.13237. View

12.

Bril F, Kalavalapalli S, Clark V, Lomonaco R, Soldevila-Pico C, Liu I . Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. Clin Gastroenterol Hepatol. 2017; 16(4):558-566.e2. DOI: 10.1016/j.cgh.2017.12.001. View

13.

Sosale A, Saboo B, Sosale B . Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence. Diabetes Metab Syndr Obes. 2015; 8:189-96. PMC: 4403747. DOI: 10.2147/DMSO.S49592. View

14.

Fan N, Zhang L, Xia Z, Peng L, Wang Y, Peng Y . Sex-Specific Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients. J Diabetes Res. 2016; 2016:3805372. PMC: 4921134. DOI: 10.1155/2016/3805372. View

15.

Taheri H, Malek M, Ismail-Beigi F, Zamani F, Sohrabi M, Babaei M . Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Adv Ther. 2020; 37(11):4697-4708. PMC: 7547956. DOI: 10.1007/s12325-020-01498-5. View

16.

Kaul U, Parmar D, Manjunath K, Shah M, Parmar K, Patil K . New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovasc Diabetol. 2019; 18(1):80. PMC: 6580520. DOI: 10.1186/s12933-019-0884-3. View

17.

Beaton M . Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol. 2012; 26(6):353-7. PMC: 3378283. DOI: 10.1155/2012/725468. View

18.

Pai V, Paneerselvam A, Mukhopadhyay S, Bhansali A, Kamath D, Shankar V . A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V). J Diabetes Sci Technol. 2014; 8(1):132-141. PMC: 4390522. DOI: 10.1177/1932296813518680. View